Pharmigene (7595.TWO) Stock Price

Pharmigene Price

CLOSED
7.70
​
Market closed

Over the last 8 years Pharmigene grew revenue by 17.5% annually, reaching 199.89 M TWD. For Pharmigene, the net margin of -36.5% is down versus -18.1% a few years ago.

Pharmigene stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmigene business model & stock analysis

Pharmigene, Inc. generates revenue through the manufacturing and sale of pharmaceutical genetic diagnostic products, including AutoEx16 automatic nucleic acid extractors, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kits, and SGE 1502, SGE 3101, SGE 5701, Sega 5801, SGE B27, and SGE whole blood calculation and extraction kits. The company offers molecular diagnostic products and testing services such as drug genetic testing, functional medical testing, and personalized genetic testing. Its primary market is Taiwan, with additional presence in other markets. The firm focuses on genomics science for precision medicine, targeting research and development in drug genomics. Pharmigene's product portfolio includes specialized kits for drug genetic testing, such as the Clopidogrel test kit, which assesses genetic variations affecting drug efficacy. The SGE test suites and kits are designed for various diagnostic applications, including whole blood processing and genetic analysis. The company distributes these products through its established market channels in Taiwan and other regions, emphasizing professional solutions for precision medicine. The firm's testing services cater to healthcare providers and research institutions seeking tailored genetic insights. The company's revenue streams are derived from the direct sale of diagnostic kits, testing services, and overall solutions for drug genomics research. Its target segments include healthcare providers, research institutions, and precision medicine developers in Taiwan and other markets. Pharmigene's focus on genetic diagnostic technologies positions it within the niche of pharmaceutical genomics, serving clients who require advanced molecular diagnostics for personalized healthcare approaches.

Frequently asked questions about Pharmigene

Converted at the current exchange rate, the Pharmigene share trades at 0.21 EUR (7.70 TWD).

The revenue cannot currently be calculated for Pharmigene.

The profit cannot currently be calculated for Pharmigene.

The P/E ratio cannot be calculated for Pharmigene at the moment.

The P/S cannot be calculated for Pharmigene currently.

The Eulerpool Quality Score for Pharmigene is 3/10.

The ISIN of Pharmigene is TW0007595B13. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Pharmigene is 7595.TWO. The ticker symbol is used to trade Pharmigene shares on the stock exchange.

Fair ValueTerminal
6.54 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Dec 22, 2020
ISIN
TW0007595B13
Cusip
Y6S2DK107
Market capitalization
388.62 M TWDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.40
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-8.62 %
Last updated Oct 23, 2026, 5:34 PM

Pharmigene Peer Group

Pharmigene FIGI

7595:TT (Taipei Stock Exchange) · BBG00WK94VY7

All fundamentals and in-depth analysis of Pharmigene

Our stock analysis for Pharmigene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmigene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.